Medical Funding Professionals

Alternative Funding Strategies for Life Science Companies

We show founders and key executives in biotech, medtech, pharma, and other life sciences a path to keep more control of their company and realize higher valuations as they go through the fundraising process.




Qualified to Raise (USD)



Share Price (USD)


per share

Minimum Investment Required



Type of Share


Voting Shares

SEC Registered Transfer Agent

KoreTransfer USA


Assurance Dimensions

FINRA Broker-dealer

Rialto Markets

Escrow Agent

Equistake Financial

Offering Preparation

RegD Resources



IRA Custodian


Secondary ATS

Rialto Markets

Issuance Technology


The Democratization of Capital

In the wake of the 2008 financial crisis came not only a tightening of capital, but a tightening of the regulations related to raising capital, particularly for smaller companies. The 2012 JOBS Act changed that, by lowering the reporting and disclosure requirements for small issuers, and by allowing the advertising of securities offerings, greatly expanding the opportunities for companies to offer stock without going through a traditional stock market IPO.

In particular, Regulation A+ provides a vehicle for companies to raise up to $75 million per year from both accredited and non-accredited (“Main Street”) investors. This puts it on a level to provide capital-intensive life sciences companies a viable alternative to venture capital and private equity.

Capital Planning Valuation StrategyTM (CPVS)

CPVS is a proprietary process of Medical Funding Professionals that uses company-provided information to develop a custom, proposed pro forma presentation for your Reg A+ offering. The presentation establishes a powerful, forward-looking foundation to effectively implement a company’s capital funding strategies.